利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

304 条记录 (耗时 0.023 秒)

    Process for the separation and/or isolation of plasma proteins by means of annular chromatography
    91.
    发明申请
    Process for the separation and/or isolation of plasma proteins by means of annular chromatography 审中-公开
    通过环形色谱分离和/或分离血浆蛋白的方法

    公开(公告)号：US20020035241A1

    公开(公告)日：2002-03-21

    申请号：US09879814

    申请日：2001-06-13

    发明人： Andrea Buchacher ,  Djuro Josic ,  Gerhard Gruber

    IPC分类号： C07K014/745 ,  C07K001/16

    CPC分类号： C12N9/644 ,  C07K14/755 ,  C07K14/765 ,  C07K14/8125 ,  C07K16/065 ,  C12N9/6429 ,  C12N9/647 ,  C12Y304/21005 ,  C12Y304/21022

    摘要： A process separates and/or isolates plasma proteins, especially human plasma proteins, from a mixture containing plasma proteins, wherein the mixture is applied to a separation medium having an annular design and having a layer of application medium applied thereon; the separation medium having the annular design is rotated essentially vertically about an axis which is defined in the direction of flow of the mixture through the separation medium having the annular design; an eluent is passed through the separation medium having the annular design; and fractions exiting at the end of the separation medium having the annular design are collected.

    摘要翻译： 一种方法从含有血浆蛋白质的混合物中分离和/或分离血浆蛋白质，特别是人血浆蛋白质，其中将混合物施用于具有环形设计并具有施加在其上的施用介质层的分离介质; 具有环形设计的分离介质基于在通过具有环形设计的分离介质的混合物的流动方向限定的轴线基本垂直地旋转; 洗脱液通过具有环形设计的分离介质; 并且收集在具有环形设计的分离介质的末端处离开的馏分。

    Pathogen-targeted biocatalysts
    92.
    发明授权
    Pathogen-targeted biocatalysts 失效
    病原体靶向生物催化剂

    公开(公告)号：US06287561B1

    公开(公告)日：2001-09-11

    申请号：US09410882

    申请日：1999-10-04

    申请人： Roberto Crea

    发明人： Roberto Crea

    IPC分类号： A61K3942

    CPC分类号： C07K14/70514 ,  C07K2319/01 ,  C07K2319/035 ,  C12N9/6429 ,  C12N9/6459 ,  C12N9/6462 ,  C12Y304/21005 ,  C12Y304/21069 ,  C12Y304/21073

    摘要： This invention pertains to biocatalysts that are specifically targeted to bind pathogens, such as viruses, and to degrade components of pathogens in order to abrogate their pathogenicity, and to methods of preventing or treating infection by pathogenic organisms. The biocatalysts comprise a binding agent which specifically binds a surface component of a pathogen, for instance the gp120 viral coat protein of the Human Immunodeficiency Virus, and a catalytic moiety which degrades a component of the pathogen so that its pathogenicity is abrogated. The binding agent and the catalytic moiety are linked by chemical linkers or genetic engineering techniques.

    摘要翻译： 本发明涉及特异性靶向于结合病原体如病毒并降解病原体成分​​以消除其致病性的生物催化剂，以及预防或治疗病原体感染的方法。 生物催化剂包括特异性结合病原体的表面组分的结合剂，例如人免疫缺陷病毒的gp120病毒外壳蛋白，以及降解病原体成分​​以使其致病性被废除的催化部分。 结合剂和催化部分通过化学接头或遗传工程技术连接。

    Stable recombinant meizothrombin-like polypeptides
    98.
    发明授权
    Stable recombinant meizothrombin-like polypeptides 失效
    稳定的重组甲硫菌素样多肽

    公开(公告)号：US5510248A

    公开(公告)日：1996-04-23

    申请号：US82843

    申请日：1993-06-22

    申请人： Helene C. F. Cote ,  Willem K. Stevens ,  Michael E. Nesheim ,  Ross T. A. MacGillivray

    发明人： Helene C. F. Cote ,  Willem K. Stevens ,  Michael E. Nesheim ,  Ross T. A. MacGillivray

    IPC分类号： A61K38/00 ,  C12N9/74 ,  C12P21/02 ,  C07H21/04 ,  C12N5/10 ,  C12N15/11

    CPC分类号： C12N9/6429 ,  C12Y304/21005 ,  A61K38/00

    摘要： An isolated polynucleotide which encodes human prothrombin is modified to encode amino acid substitutions at positions 155, 271 and 284 of the prothrombin polypeptide. A second polynucleotide is further modified to encode an additional amino acid substitution at residue 320.The polypeptide encoded by the first polynucleotide is resistant to cleavage by thrombin and factor Xa, exhibits greatly reduced procoagulant activity towards fibrinogen and unchanged anticoagulant activity towards protein C. The polypeptide can be cleaved between amino acid positions 320 and 321 to produce an active serine protease which can activate protein C, thereby inhibiting coagulation and stimulating activated protein C fibrinolytic activity.The polypeptide encoded by the second polynucleotide cannot be cleaved, mimics inactive prothrombin and thereby acts as a reversible inhibitor of coagulation by competing with Factor Xa and Factor Va for interaction at the phospholipid surface.Methods of producing recombinant polypeptides using the two isolated, modified polynucleotides are described.

    摘要翻译： 修饰编码人凝血酶原的分离的多核苷酸以在凝血酶原多肽的位置155,271和284处编码氨基酸取代。 进一步修饰第二个多核苷酸以在残基320处编码另外的氨基酸取代。由第一多核苷酸编码的多肽对凝血酶和因子Xa的切割具有抗性，显示出大大降低了对纤维蛋白原的促凝活性和对蛋白C的不变的抗凝血活性。 可以在氨基酸位置320和321之间切割多肽，以产生能活化蛋白C的活性丝氨酸蛋白酶，从而抑制凝血并刺激活化的蛋白C纤维蛋白溶解活性。 由第二多核苷酸编码的多肽不能被切割，模拟无活性凝血酶原，从而通过与因子Xa和因子Va竞争在磷脂表面上相互作用而作为可逆的凝血抑制剂。 描述了使用两个分离的修饰的多核苷酸产生重组多肽的方法。

    Process for preparing a human thrombin concentrate intended for therapeutic use
    99.
    发明授权
    Process for preparing a human thrombin concentrate intended for therapeutic use 失效
    制备用于治疗用途的人凝血酶浓缩物的方法

    公开(公告)号：US5304372A

    公开(公告)日：1994-04-19

    申请号：US913933

    申请日：1992-07-17

    申请人： Catherine Michalski ,  Dominique Dernis

    发明人： Catherine Michalski ,  Dominique Dernis

    IPC分类号： A61K38/48 ,  A61K38/00 ,  A61P7/04 ,  C12N9/74 ,  A61K35/14 ,  C07K3/00 ,  C07K13/00

    CPC分类号： C12N9/6429 ,  C12Y304/21005 ,  A61K38/00

    摘要： Process for preparing a human thrombin concentrate from the PPSB fraction of plasma that does not involve any addition of factors of animal origin to induce activation of the prothrombin to produce thrombin, and which includes a viral inactivation step using solvent-detergent and purification by cation exchange chromatography. The choice of a protective medium ensures the high specific activity of the final product. The thrombin concentrate obtained using this process is intended for therapeutic use, either alone, to serve as a local hemostatic agent, or in combination with a fibrinogen concentrate to form biological glue.

    摘要翻译： 从血浆PPSB级分制备人凝血酶浓缩物的方法，其不涉及动物来源的任何因素来诱导凝血酶原激活以产生凝血酶，并且其包括使用溶剂洗涤剂和通过阳离子交换纯化的病毒灭活步骤 色谱法。 保护介质的选择确保最终产品的高比活性。 使用该方法获得的凝血酶浓缩物单独用于治疗用途，用作局部止血剂，或与纤维蛋白原浓缩物组合以形成生物胶。